Skip to main content
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. — Investor Relations & Filings

Ticker · OVID ISIN · US6904691010 LEI · 549300H36NUI4L6U8F17 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2024-05-14 Capital/Financing Update
Country US United States of America
Listing US OVID

About Ovid Therapeutics Inc.

https://ovidrx.com/

Ovid Therapeutics Inc. is a biopharmaceutical company that develops targeted small molecule therapies for neurological conditions. The company's primary focus is on conquering epilepsies and other brain disorders by creating treatments that aim to reduce seizures and offer improved safety and tolerability. Ovid's scientific approach involves pioneering compounds with unique or potentially best-in-class mechanisms of action to address significant unmet medical needs. The company's mission is to develop medicines that improve the lives of patients and families affected by these conditions.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Ovid Therapeutics Inc. on May 14, 2024. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans. The document includes details about the registration of additional shares under the 2017 Equity Incentive Plan, references to prior filings, and exhibits related to the plan and legal opinions. It is not a financial report, earnings release, or management discussion, but a registration statement related to capital structure and equity compensation plans. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2024-05-14 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 14, 2024, by Ovid Therapeutics Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing the first quarter 2024 financial results. The document states that the press release is furnished as an exhibit and incorporated by reference, and the text itself does not contain detailed financial statements or substantive financial data but rather a summary and reference to the press release. The document length is 3634 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release with financial results but does not contain the full financial data itself should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2024-05-14 English
ARS
Annual Report
2024-04-24 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly mentions 'Proxy Statement' and 'Definitive Additional Materials,' indicating it is related to proxy solicitation and shareholder voting information. The document is not a full annual report, earnings release, or other financial report but rather materials associated with shareholder meetings and voting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is short and consistent with proxy materials rather than a full report.
2024-04-24 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.